pembrolizumab
merck
['melanoma', 'pembro']
in a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma. presented at aacr 2023. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.